List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2026725/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Response to: â€~External validation of EULAR/ACR classification criteria for idiopathic inflammatory myopathies' by Luu <i>et al</i> . Annals of the Rheumatic Diseases, 2022, 81, e60-e60.	0.9	0
2	Forearm porphyrin levels evaluated by digital imaging system are increased in patients with systemic sclerosis compared with patients in pre-clinical stage. Intractable and Rare Diseases Research, 2022, 11, 1-6.	0.9	0
3	Human Leukocyte Antigens and Biomarkers in Type 1 Diabetes Mellitus Induced by Immune-Checkpoint Inhibitors. Endocrinology and Metabolism, 2022, 37, 84-95.	3.0	17
4	Dupilumab Improves Pruritus in Netherton Syndrome: A Case Study. Children, 2022, 9, 310.	1.5	8
5	ISSVA Classification of Vascular Anomalies and Molecular Biology. International Journal of Molecular Sciences, 2022, 23, 2358.	4.1	79
6	Elevated Alpha 1(I) to Alpha 2(I) Collagen Ratio in Dermal Fibroblasts Possibly Contributes to Fibrosis in Systemic Sclerosis. International Journal of Molecular Sciences, 2022, 23, 6811.	4.1	4
7	Case of tufted angioma treated successfully with tranilast, topical steroids and tacrolimus ointment. Journal of Dermatology, 2021, 48, e84-e85.	1.2	0
8	Validation of measurement scores for evaluating vascular anomaly skin lesions. Journal of Dermatology, 2021, 48, 993-998.	1.2	0
9	yRNA3 up-regulation in cultured dermal fibroblasts and yRNA4 down-regulation in the sera of scleroderma patients. Journal of Dermatological Science, 2021, 102, 68-71.	1.9	2
10	The clinical significance of cytokeratin 20 staining pattern in Merkel cell carcinoma. Drug Discoveries and Therapeutics, 2021, 15, 162-165.	1.5	4
11	Analysis of onset and clinical characteristics in Japanese patients with infantile hemangioma. Drug Discoveries and Therapeutics, 2021, 15, 210-213.	1.5	4
12	A case of dermatofibrosarcoma protuberans with <i>COL1A1-PDGFB</i> fusion gene. Skin Cancer, 2021, 36, 55-59.	0.0	0
13	Efficacy and Safety of Sodium Thiosulfate in Japanese Patients with Calciphylaxis. International Journal of Surgical Wound Care, 2021, 2, 7-14.	0.1	1
14	First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort. Annals of the Rheumatic Diseases, 2020, 79, 387-392.	0.9	17
15	Adipophilin expression in cutaneous malignant melanoma is associated with high proliferation and poor clinical prognosis. Laboratory Investigation, 2020, 100, 727-737.	3.7	24
16	MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma. Journal of Dermatological Science, 2020, 97, 77-79.	1.9	13
17	Effect of topical immunotherapy with squaric acid dibutylester for alopecia areata in Japanese patients. Allergology International, 2020, 69, 274-278.	3.3	7
18	Characteristics of Japanese patients with eosinophilic fasciitis: A brief multicenter study. Journal of Dermatology, 2020, 47, 1391-1394.	1.2	3

#	Article	IF	CITATIONS
19	Change of serum cytokine profiles by propranolol treatment in patients with infantile hemangioma. Drug Discoveries and Therapeutics, 2020, 14, 89-92.	1.5	5
20	Effects of lowâ€dose <i>Aloe</i> sterol supplementation on skin moisture, collagen score and objective or subjective symptoms: 12â€week, doubleâ€blind, randomized controlled trial. Journal of Dermatology, 2020, 47, 998-1006.	1.2	4
21	Japanese Clinical Practice Guidelines for Vascular Anomalies 2017. Journal of Dermatology, 2020, 47, e138-e183.	1.2	6
22	Japanese clinical practice guidelines for vascular anomalies 2017. Pediatrics International, 2020, 62, 260-307.	0.5	7
23	Japanese clinical practice guidelines for vascular anomalies 2017. Japanese Journal of Radiology, 2020, 38, 287-342.	2.4	16
24	â€~Narrow-sense' and â€~broad-sense' vascular abnormalities of systemic sclerosis. Immunological Medicine, 2020, 43, 107-114.	2.6	8
25	Primary cutaneous peripheral Tâ€cell lymphoma, not otherwise specified, associated with lymphomatoid papulosis after a 9â€year follow up: A case report. Journal of Dermatology, 2020, 47, 641-645.	1.2	1
26	Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immuneâ€checkpoint inhibitors. Cancer Science, 2020, 111, 1468-1477.	3.9	86
27	Bilateral Eyebrow Sclerosis. Plastic and Reconstructive Surgery - Global Open, 2020, 8, e2883.	0.6	0
28	A successful case of lupus myelitis treated with intravenous pulse methylprednisolone and pulse cyclophosphamide therapy. Drug Discoveries and Therapeutics, 2020, 14, 209-210.	1.5	1
29	Distribution analysis of infantile hemangioma or capillary malformation on the head and face in Japanese patients. Journal of Dermatology, 2019, 46, 849-852.	1.2	10
30	A potential significance of circ_0024169 down regulation in angiosarcoma tissue. Intractable and Rare Diseases Research, 2019, 8, 129-133.	0.9	8
31	Overexpression of cyclinâ€dependent kinase 4 protein in extramammary Paget's disease. Journal of Dermatology, 2019, 46, 444-448.	1.2	12
32	Serum cellâ€free DNA levels are a useful marker for extramammary Paget disease. British Journal of Dermatology, 2019, 181, 505-511.	1.5	10
33	Recurrent Fusion Gene ADCK4-NUMBL in Cutaneous Squamous Cell Carcinoma MediatesÂCellÂProliferation. Journal of Investigative Dermatology, 2019, 139, 954-957.	0.7	7
34	Clinical and histological evaluation of a single high energy microwave treatment for primary axillary hyperhidrosis in Asians: A prospective, randomized, controlled, splitâ€area comparative trial. Lasers in Surgery and Medicine, 2019, 51, 592-599.	2.1	12
35	Royal jelly regulates the proliferation of human dermal microvascular endothelial cells through the down-regulation of a photoaging-related microRNA. Drug Discoveries and Therapeutics, 2019, 13, 268-273.	1.5	7
36	High-Risk Human Papillomavirus E6/E7 mRNA Is Rarely Detected in Nonanogenital Cutaneous Squamous Cell Carcinoma: An RNA In Situ Hybridization–Based Tissue Microarray Study. American Journal of Dermatopathology, 2019, 41, 205-210.	0.6	11

#	Article	IF	CITATIONS
37	Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma. Journal of Dermatological Science, 2019, 93, 33-40.	1.9	15
38	A case of slowly progressing angiosarcoma. Skin Cancer, 2019, 34, 41-45.	0.0	0
39	Merkel cell carcinoma development in the presence of Bowen's disease : a case report. Skin Cancer, 2019, 34, 160-164.	0.0	0
40	Diagnostic criteria, severity classification and guidelines of localized scleroderma. Journal of Dermatology, 2018, 45, 755-780.	1.2	51
41	Diagnostic criteria, severity classification and guidelines of systemic sclerosis. Journal of Dermatology, 2018, 45, 633-691.	1.2	35
42	Impact of a new simplified disability scoring system for adult patients with localized scleroderma. Journal of Dermatology, 2018, 45, 431-435.	1.2	2
43	Splicing variant of <i>WDFY4</i> augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Annals of the Rheumatic Diseases, 2018, 77, 602-611.	0.9	51
44	Case of pigmented lipofibromatosis in a 27â€yearâ€old woman. Journal of Dermatology, 2018, 45, e128-e129.	1.2	2
45	Diagnostic criteria, severity classification and guidelines of lichen sclerosus et atrophicus. Journal of Dermatology, 2018, 45, 891-897.	1.2	17
46	Regulatory mechanisms of collagen expression by interleukin-22 signaling in scleroderma fibroblasts. Journal of Dermatological Science, 2018, 90, 52-59.	1.9	18
47	A case report of atypical Spitz tumor harboring a novel MLPH-ALK gene fusion with discordant ALK immunohistochemistry results. Human Pathology, 2018, 80, 99-103.	2.0	11
48	Diagnostic criteria, severity classification and guidelines of eosinophilic fasciitis. Journal of Dermatology, 2018, 45, 881-890.	1.2	50
49	Serum cytokine profiles are altered in patients with progressive infantile hemangioma. BioScience Trends, 2018, 12, 438-441.	3.4	6
50	Prognostic factors of daily blood examination for advanced melanoma patients treated with nivolumab. BioScience Trends, 2018, 12, 412-418.	3.4	13
51	Systemic lupus erythematosus associated with myasthenia gravis, pemphigus foliaceus and chronic thyroiditis after thymectomy. Australasian Journal of Dermatology, 2017, 58, e120-e122.	0.7	19
52	Inhibition of heat shock protein 90 exerts an antitumour effect in angiosarcoma: involvement of the vascular endothelial growth factor signalling pathway. British Journal of Dermatology, 2017, 177, 456-469.	1.5	16
53	Diagnosis of nail psoriasis: evaluation of nail-derived microRNAs as potential novel biomarkers. European Journal of Dermatology, 2017, 27, 20-27.	0.6	6
54	Transforming growth factor βâ€inhibitor Repsox downregulates collagen expression of scleroderma dermal fibroblasts and prevents bleomycinâ€induced mice skin fibrosis. Experimental Dermatology, 2017, 26, 1139-1143.	2.9	17

#	Article	IF	CITATIONS
55	RXRB Is an MHC-Encoded Susceptibility Gene Associated with Anti-Topoisomerase lÂAntibody-Positive Systemic Sclerosis. Journal of Investigative Dermatology, 2017, 137, 1878-1886.	0.7	3
56	Serum levels of genomic DNA of α1(I) collagen are elevated in scleroderma patients. Journal of Dermatology, 2017, 44, 927-931.	1.2	1
57	Cutaneous spindle cell adenolipoma on the nose: A rare variant of lipoma. Journal of Dermatology, 2017, 44, e156-e157.	1.2	2
58	Transethnic meta-analysis identifies <i>CSDMA</i> and <i>PRDM1</i> as susceptibility genes to systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1150-1158.	0.9	77
59	Achieved good response of Sâ€1 and docetaxel combination chemotherapy in two patients with metastatic extramammary Paget's disease. Journal of Dermatology, 2017, 44, e103-e104.	1.2	20
60	Chronic sun exposure-related fusion oncogenes EGFR-PPARGC1A in cutaneous squamous cell carcinoma. Scientific Reports, 2017, 7, 12654.	3.3	16
61	Secukinumabâ€induced interstitial pneumonia in a patient with psoriasis vulgaris. Journal of Dermatology, 2017, 44, e322-e323.	1.2	11
62	S100A7 expression levels in coordination with interleukinâ€8 indicate the clinical response to infliximab for psoriasis patients. Journal of Dermatology, 2017, 44, 838-839.	1.2	7
63	Dysregulated interleukin-23 signalling contributes to the increased collagen production in scleroderma fibroblasts via balancing microRNA expression. Rheumatology, 2017, 56, 145-155.	1.9	27
64	Bromoderma in a pituitary adenoma patient treated with bromocriptine. Journal of Dermatology, 2017, 44, e95-e96.	1.2	6
65	The role of miR-210, E2F3 and ephrin A3 in angiosarcoma cell proliferation. European Journal of Dermatology, 2017, 27, 464-471.	0.6	20
66	Bullous dermatosis on legs of elderly: A new clinical entity?. Drug Discoveries and Therapeutics, 2017, 11, 346-348.	1.5	1
67	Intratumor dihydropyrimidine dehydrogenase mRNA expression levels are decreased in extramammary Paget's disease. Drug Discoveries and Therapeutics, 2017, 11, 152-155.	1.5	2
68	Do scleroderma patients look young?: Evaluation by using facial imaging system. Drug Discoveries and Therapeutics, 2017, 11, 342-345.	1.5	4
69	Treatment of psoriasis with ustekinumab improved skin tightening in systemic sclerosis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 208-210.	0.8	3
70	Symptomless Pulmonary Cryptococcosis in a Psoriatic Arthritis Patient during Infliximab Therapy. Annals of Dermatology, 2016, 28, 269.	0.9	1
71	Exome sequence analysis of Kaposiform hemangioendothelioma: identification of putative driver mutations. Anais Brasileiros De Dermatologia, 2016, 91, 748-753.	1.1	4
72	Cytokine expression profiles in the sera of cutaneous squamous cell carcinoma patients. Drug Discoveries and Therapeutics, 2016, 10, 172-176.	1.5	6

#	Article	IF	CITATIONS
73	The expression of miR-124 increases in aged skin to cause cell senescence and it decreases in squamous cell carcinoma. BioScience Trends, 2016, 10, 454-459.	3.4	23
74	Cell division cycleâ€associated protein 1 as a new melanomaâ€associated antigen. Journal of Dermatology, 2016, 43, 1399-1405.	1.2	14
75	Altered expression of CD63 and exosomes in scleroderma dermal fibroblasts. Journal of Dermatological Science, 2016, 84, 30-39.	1.9	53
76	Intratumoral expression levels of <i>PD-L1</i> , <i>GZMA</i> , and <i>HLA-A</i> along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. Oncolmmunology, 2016, 5, e1204507.	4.6	107
77	Long non-coding RNA TSIX is upregulated in scleroderma dermal fibroblasts and controls collagen mRNA stabilization. Experimental Dermatology, 2016, 25, 131-136.	2.9	62
78	Enhanced CCR9 expression levels in psoriatic skin are associated with poor clinical outcome to infliximab treatment. Journal of Dermatology, 2016, 43, 522-525.	1.2	7
79	micro <scp>RNA</scp> level is raised in the hair shafts of patients with dematomyositis in comparison with normal subjects and patients with scleroderma. International Journal of Dermatology, 2016, 55, 786-790.	1.0	3
80	Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Science, 2016, 107, 1055-1058.	3.9	176
81	Establishment and gene expression analysis of disease-derived induced pluripotent stem cells of scleroderma. Journal of Dermatological Science, 2016, 84, 186-196.	1.9	10
82	Genetic and epigenetic abnormalities in systemic sclerosis. Journal of Dermatology, 2016, 43, 10-18.	1.2	25
83	Serum long nonâ€eoding RNA, snoRNA host gene 5 level as a new tumor marker of malignant melanoma. Experimental Dermatology, 2016, 25, 67-69.	2.9	47
84	Upregulation of ANGPTL6 in mouse keratinocytes enhances susceptibility to psoriasis. Scientific Reports, 2016, 6, 34690.	3.3	12
85	A possible mechanism of hypercoagulation status in scleroderma. British Journal of Dermatology, 2016, 174, 263-263.	1.5	0
86	The role of PSMB9 upregulated by interferon signature in the pathophysiology of cutaneous lesions of dermatomyositis and systemic lupus erythematosus. British Journal of Dermatology, 2016, 174, 1030-1041.	1.5	23
87	Immunotherapy against Metastatic Melanoma with Human iPS Cell–Derived Myeloid Cell Lines Producing Type I Interferons. Cancer Immunology Research, 2016, 4, 248-258.	3.4	20
88	A Case of Systemic Sclerosis with Interstitial Lung Disease Successfully Treated with Intravenous Cyclophosphamide Pulse Therapy and Oral Azathioprine. Nishinihon Journal of Dermatology, 2016, 78, 356-361.	0.0	0
89	Recent progress in studies of mi <scp>RNA</scp> and skin diseases. Journal of Dermatology, 2015, 42, 551-558.	1.2	27
90	Serum miR-124 up-regulation as a disease marker of toxic epidermal necrolysis. European Journal of Dermatology, 2015, 25, 457-462.	0.6	17

#	Article	IF	CITATIONS
91	Hair shaft mi <scp>RNA</scp> â€221 levels as a new tumor marker of malignant melanoma. Journal of Dermatology, 2015, 42, 198-201.	1.2	7
92	Biweekly gemcitabine therapy induces complete remission in cutaneous angiosarcoma resistant to multiple anticancer drugs. Journal of Dermatology, 2015, 42, 1197-1198.	1.2	8
93	Serum concentrations of Flt-3 ligand in rheumatic diseases. BioScience Trends, 2015, 9, 342-349.	3.4	3
94	Mice overexpressing integrin $\hat{l}_{\pm v}$ in fibroblasts exhibit dermal thinning of the skin. Journal of Dermatological Science, 2015, 79, 268-278.	1.9	9
95	Prognostic Significance of CD169+ Lymph Node Sinus Macrophages in Patients with Malignant Melanoma. Cancer Immunology Research, 2015, 3, 1356-1363.	3.4	66
96	NUP160–SLC43A3 Is a Novel Recurrent Fusion Oncogene in Angiosarcoma. Cancer Research, 2015, 75, 4458-4465.	0.9	42
97	EBI3 Downregulation Contributes to Type I Collagen Overexpression in Scleroderma Skin. Journal of Immunology, 2015, 195, 3565-3573.	0.8	27
98	Platelet-rich plasma therapy is effective for the treatment of refractory skin ulcers in patients with systemic sclerosis. Modern Rheumatology, 2015, 25, 660-661.	1.8	5
99	Investigation of FOXM1 as a Potential New Target for Melanoma. PLoS ONE, 2015, 10, e0144241.	2.5	35
100	Knockout of Endothelial Cell-Derived Endothelin-1 Attenuates Skin Fibrosis but Accelerates Cutaneous Wound Healing. PLoS ONE, 2014, 9, e97972.	2.5	21
101	Clinical Significance of Serum Vascular Endothelial-Cadherin Levels in Inflammatory Skin Diseases. Annals of Dermatology, 2014, 26, 536.	0.9	3
102	Down-regulation of microRNA-196a in the sera and involved skin of localized scleroderma patients. European Journal of Dermatology, 2014, 24, 470-476.	0.6	28
103	<scp>MIRSNP</scp> rs2910164 of mi <scp>R</scp> â€146a is associated with the muscle involvement in polymyositis/dermatomyositis. International Journal of Dermatology, 2014, 53, 300-304.	1.0	17
104	miRâ€424 levels in hair shaft are increased in psoriatic patients. Journal of Dermatology, 2014, 41, 382-385.	1.2	23
105	Serum levels of matrix metalloproteinaseâ€13 in patients with eosinophilic fasciitis. Journal of Dermatology, 2014, 41, 746-748.	1.2	10
106	Angiopoietin-like Protein 2 Accelerates Carcinogenesis by Activating Chronic Inflammation and Oxidative Stress. Molecular Cancer Research, 2014, 12, 239-249.	3.4	56
107	Successful treatment of skin fistulas in systemic sclerosis patients with the combination of topical negative pressure therapy and split-thickness skin grafting. Modern Rheumatology, 2014, 24, 374-376.	1.8	3
108	miR-205 down-regulation promotes proliferation of dermatofibrosarcoma protuberans tumor cells by regulating LRP-1 and ERK phosphorylation. Archives of Dermatological Research, 2014, 306, 367-374.	1.9	12

#	Article	IF	CITATIONS
109	Decreased Interleukinâ€20 Expression in Scleroderma Skin Contributes to Cutaneous Fibrosis. Arthritis and Rheumatology, 2014, 66, 1636-1647.	5.6	14
110	Analysis of expression pattern of serum microRNA levels in patients with psoriasis. Journal of Dermatological Science, 2014, 74, 170-171.	1.9	22
111	Upregulation of miR-18a-5p contributes to epidermal necrolysis in severe drug eruptions. Journal of Allergy and Clinical Immunology, 2014, 133, 1065-1074.	2.9	50
112	Various applications of microRNAs in skin diseases. Journal of Dermatological Science, 2014, 74, 3-8.	1.9	26
113	Detection of hair-microRNAs as the novel potent biomarker: Evaluation of the usefulness for the diagnosis of scleroderma. Journal of Dermatological Science, 2013, 72, 134-141.	1.9	40
114	Serum levels of tenascinâ€≺scp>C in collagen diseases. Journal of Dermatology, 2013, 40, 715-719.	1.2	16
115	Scleroderma dermal fibroblasts overexpress vascular endothelial growth factor due to autocrine transforming growth factor <i>l²</i> signaling. Modern Rheumatology, 2013, 23, 516-524.	1.8	19
116	Down-regulation of miR-124/-214 in cutaneous squamous cell carcinoma mediates abnormal cell proliferation via the induction of ERK. Journal of Molecular Medicine, 2013, 91, 69-81.	3.9	77
117	microRNA-7 down-regulation mediates excessive collagen expression in localized scleroderma. Archives of Dermatological Research, 2013, 305, 9-15.	1.9	58
118	The miR-146a rs2910164 C/G polymorphism is associated with telangiectasia in systemic sclerosis. Clinical and Experimental Dermatology, 2013, 38, 99-100.	1.3	19
119	miR-150 Down-Regulation Contributes to the Constitutive Type I Collagen Overexpression in Scleroderma Dermal Fibroblasts via the Induction ofÂIntegrin β3. American Journal of Pathology, 2013, 182, 206-216.	3.8	124
120	Successful treatment of skin fistulas in systemic sclerosis patients with the combination of topical negative pressure therapy and split-thickness skin grafting. Modern Rheumatology, 2013, , 1.	1.8	0
121	Discoidin Domain Receptor 2–microRNA 196a–Mediated Negative Feedback against Excess Type I Collagen Expression Is Impaired in Scleroderma Dermal Fibroblasts. Journal of Investigative Dermatology, 2013, 133, 110-119.	0.7	39
122	Decreased miR-7 Expression in the Skin and Sera of Patients with Dermatomyositis. Acta Dermato-Venereologica, 2013, 93, 273-276.	1.3	31
123	The rs2910164 G>C polymorphism in microRNA-146a is associated with the incidence of malignant melanoma. Melanoma Research, 2013, 23, 13-20.	1.2	31
124	Sensitive detection of melanoma metastasis using circulating microRNA expression profiles. Melanoma Research, 2013, 23, 366-372.	1.2	57
125	The Downregulation of microRNA let-7a Contributes to the Excessive Expression of Type I Collagen in Systemic and Localized Scleroderma. Journal of Immunology, 2013, 190, 3905-3915.	0.8	142
126	Geographical Flushing of the Children's Face: A New Clinical Entity?. Case Reports in Dermatological Medicine, 2013, 2013, 1-2.	0.3	0

#	Article	IF	CITATIONS
127	Hair miR-29a levels are decreased in patients with scleroderma. Experimental Dermatology, 2013, 22, 832-833.	2.9	27
128	Role of c-Jun N-terminal kinase isoforms in the cellular activity of melanoma cell lines. Clinical and Experimental Dermatology, 2013, 38, 890-896.	1.3	11
129	Expression analysis of multiple micro <scp>RNA</scp> s in each patient with scleroderma. Experimental Dermatology, 2013, 22, 489-491.	2.9	25
130	Contribution of miRNAs to the pathogenesis of scleroderma and targeting them for the diagnosis and treatment. Expert Review of Dermatology, 2013, 8, 417-426.	0.3	1
131	THU0259â€The levels of adiponectin are decreased in the skin and sera of diffuse cutaneous systemic sclerosis patients. Annals of the Rheumatic Diseases, 2013, 71, 242.2-242.	0.9	0
132	Down-regulation of miR-223 contributes to the formation of Gottron's papules in dermatomyositis via the induction of PKCε. European Journal of Dermatology, 2013, 23, 160-167.	0.6	29
133	Detection of hair root miR-19a as a novel diagnostic marker for psoriasis. European Journal of Dermatology, 2013, 23, 807-811.	0.6	20
134	Scleroderma dermal fibroblasts overexpress vascular endothelial growth factor due to autocrine transforming growth factor l² signaling. Modern Rheumatology, 2013, 23, 516-524.	1.8	11
135	Serum levels of leptin receptor in patients with systemic sclerosis. Intractable and Rare Diseases Research, 2013, 2, 55-8.	0.9	1
136	Serum miR-21 levels in patients with dermatomyositis. Clinical and Experimental Rheumatology, 2013, 31, 161-2.	0.8	10
137	Impaired IL-17 Signaling Pathway Contributes to the Increased Collagen Expression in Scleroderma Fibroblasts. Journal of Immunology, 2012, 188, 3573-3583.	0.8	188
138	microRNA-92a expression in the sera and dermal fibroblasts increases in patients with scleroderma. Rheumatology, 2012, 51, 1550-1556.	1.9	97
139	TGF-β–Mediated Downregulation of MicroRNA-196a Contributes to the Constitutive Upregulated Type I Collagen Expression in Scleroderma Dermal Fibroblasts. Journal of Immunology, 2012, 188, 3323-3331.	0.8	138
140	Overexpression of hepatocyte growth factor receptor in scleroderma dermal fibroblasts is caused by autocrine transforming growth factor $\hat{l}^2$ signaling. BioScience Trends, 2012, 6, 136-42.	3.4	10
141	Increased serum levels of miR-1266 in patients with psoriasis vulgaris. European Journal of Dermatology, 2012, 22, 68-71.	0.6	48
142	Increased Accumulation of Extracellular Thrombospondin-2 Due to Low Degradation Activity Stimulates Type I Collagen Expression in Scleroderma Fibroblasts. American Journal of Pathology, 2012, 180, 703-714.	3.8	53
143	Clinical significance of cobblestone appearance on the skin of patients with systemic sclerosis. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 123-125.	2.4	0
144	Circulating miR-142-3p levels in patients with systemic sclerosis. Clinical and Experimental Dermatology, 2012, 37, 34-39.	1.3	88

#	Article	IF	CITATIONS
145	Serum levels of soluble CD163 in patients with systemic sclerosis. Rheumatology International, 2012, 32, 403-407.	3.0	41
146	Circulating miR-29a levels in patients with scleroderma spectrum disorder. Journal of Dermatological Science, 2011, 61, 67-69.	1.9	58
147	Circulating microRNA associated with TNF-α signaling pathway in patients with plaque psoriasis. Journal of Dermatological Science, 2011, 61, 209-211.	1.9	17
148	The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. Journal of Dermatological Science, 2011, 61, 187-193.	1.9	185
149	Expression of Matrix Metalloproteinase-13 Is Controlled by IL-13 via PI3K/Akt3 and PKC-δ in Normal Human Dermal Fibroblasts. Journal of Investigative Dermatology, 2011, 131, 655-661.	0.7	48
150	The expression of HER-2 in extramammary Paget's disease. BioScience Trends, 2011, 5, 151-155.	3.4	29
151	microRNA-mediated keratinocyte hyperproliferation in psoriasis vulgaris. British Journal of Dermatology, 2011, 165, 1003-1010.	1.5	99
152	Adiponectin expression is decreased in the involved skin and sera of diffuse cutaneous scleroderma patients. Experimental Dermatology, 2011, 20, 764-766.	2.9	47
153	Evaluation of usefulness of 3D views for clinical photography. BioScience Trends, 2011, 5, 211-216.	3.4	5
154	Angiopoietin-like Protein 2 Is an Important Facilitator of Inflammatory Carcinogenesis and Metastasis. Cancer Research, 2011, 71, 7502-7512.	0.9	119
155	The expression levels of thrombospondin-1 in dermatofibroma and dermatofibrosarcoma protuberans. European Journal of Dermatology, 2011, 21, 534-538.	0.6	5
156	Mechanisms of skin fibrosis in systemic sclerosis. Journal of Dermatology, 2010, 37, 11-25.	1.2	139
157	Recent progress in studies of infantile hemangioma. Journal of Dermatology, 2010, 37, 283-298.	1.2	53
158	WITHDRAWN; Recent progress in studies of infantile hemangioma. Journal of Dermatology, 2010, 37, 939-955.	1.2	26
159	Serum levels of soluble vascular endothelial growth factor receptor-2 in patients with systemic sclerosis. British Journal of Dermatology, 2010, 162, 751-758.	1.5	26
160	Basic fibroblast growth factor stimulates the proliferation of human dermal fibroblasts via the ERK1/2 and JNK pathways. British Journal of Dermatology, 2010, 162, 717-723.	1.5	88
161	Down-Regulation of mir-424 Contributes to the Abnormal Angiogenesis via MEK1 and Cyclin E1 in Senile Hemangioma: Its Implications to Therapy. PLoS ONE, 2010, 5, e14334.	2.5	102
162	Up-regulated type I collagen expression by the inhibition of Rac1 signaling pathway in human dermal fibroblasts. Biochemical and Biophysical Research Communications, 2010, 393, 101-105.	2.1	14

#	Article	IF	CITATIONS
163	Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Research and Therapy, 2010, 12, R128.	3.5	186
164	A novel COL1A1 exon 14/PDGFB fusion gene inÂdermatofibrosarcoma protuberans. European Journal of Dermatology, 2010, 20, 390-391.	0.6	2
165	Infantile Hemangioma. Journal of Craniofacial Surgery, 2009, 20, 678-684.	0.7	80
166	Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nature Medicine, 2008, 14, 1236-1246.	30.7	325
167	Involvement of the constitutive complex formation of c-Ski/SnoN with smads in the impaired negative feedback regulation of transforming growth factor β signaling in scleroderma fibroblasts. Arthritis and Rheumatism, 2007, 56, 1694-1705.	6.7	13
168	Flare-up of Dermatomyositis Along with Recurrence of Breast Cancer. Breast Journal, 2007, 13, 200-202.	1.0	21
169	Clinical features of scleroderma patients with contracture of phalanges. Clinical Rheumatology, 2007, 26, 1275-1277.	2.2	15
170	Increased Expression of Integrin αvl²5 Induces the Myofibroblastic Differentiation of Dermal Fibroblasts. American Journal of Pathology, 2006, 168, 499-510.	3.8	159
171	Potential regulatory elements of the constitutive up-regulated α2(I) collagen gene in scleroderma dermal fibroblasts. Biochemical and Biophysical Research Communications, 2006, 343, 904-909.	2.1	17
172	Upregulation of Tenascin-C Expression by IL-13 in Human Dermal Fibroblasts via the Phosphoinositide 3-kinase/Akt and the Protein Kinase C Signaling Pathways. Journal of Investigative Dermatology, 2006, 126, 551-560.	0.7	27
173	Involvement of αvβ5 Integrin in the Establishment of Autocrine TGF-β Signaling in Dermal Fibroblasts Derived from Localized Scleroderma. Journal of Investigative Dermatology, 2006, 126, 1761-1769.	0.7	80
174	Platelet derived growth factor induced tenascin-C transcription is phosphoinositide 3-kinase/Akt-dependent and mediated by Ets family transcription factors. Journal of Cellular Physiology, 2006, 206, 718-727.	4.1	36
175	Constitutively phosphorylated Smad3 interacts with Sp1 and p300 in scleroderma fibroblasts. Rheumatology, 2006, 45, 157-165.	1.9	48
176	Characterization of SIS3, a Novel Specific Inhibitor of Smad3, and Its Effect on Transforming Growth Factor-β1-Induced Extracellular Matrix Expression. Molecular Pharmacology, 2006, 69, 597-607.	2.3	390
177	Sclerosing panniculitis is associated with pulmonary hypertension in systemic sclerosis. British Journal of Dermatology, 2005, 153, 579-583.	1.5	13
178	Effects of Hepatocyte Growth Factor on the Expression of Type I Collagen and Matrix Metalloproteinase-1 in Normal and Scleroderma Dermal Fibroblasts. Journal of Investigative Dermatology, 2005, 124, 324-330.	0.7	44
179	Regulation of fibrogenic/fibrolytic genes by platelet-derived growth factor C, a novel growth factor, in human dermal fibroblasts. Journal of Cellular Physiology, 2005, 202, 510-517.	4.1	76
180	Involvement of αvβ5 integrin-mediated activation of latent transforming growth factor β1 in autocrine transforming growth factor β signaling in systemic sclerosis fibroblasts. Arthritis and Rheumatism, 2005, 52, 2897-2905.	6.7	123

#	Article	IF	CITATIONS
181	Increased Expression of Integrin αvl²3 Contributes to the Establishment of Autocrine TGF-l² Signaling in Scleroderma Fibroblasts. Journal of Immunology, 2005, 175, 7708-7718.	0.8	207
182	Â2(I) collagen gene regulation by protein kinase C signaling in human dermal fibroblasts. Nucleic Acids Research, 2005, 33, 1337-1351.	14.5	38
183	Matrix metalloproteinase-1 up-regulation by hepatocyte growth factor in human dermal fibroblasts via ERK signaling pathway involves Ets1 and Fli1. Nucleic Acids Research, 2005, 33, 3540-3549.	14.5	44
184	Constitutive Thrombospondin-1 Overexpression Contributes to Autocrine Transforming Growth Factor-β Signaling in Cultured Scleroderma Fibroblasts. American Journal of Pathology, 2005, 166, 1451-1463.	3.8	79
185	Interleukin-13 Stimulates the Transcription of the Human α2(I) Collagen Gene in Human Dermal Fibroblasts. Journal of Biological Chemistry, 2004, 279, 41783-41791.	3.4	79
186	Phosphatidylinositol 3-Kinase Is Involved in α2(I) Collagen Gene Expression in Normal and Scleroderma Fibroblasts. Journal of Immunology, 2004, 172, 7123-7135.	0.8	86
187	Serum levels of tissue inhibitor of metalloproteinase-1 and 2 in patients with eosinophilic fasciitis. British Journal of Dermatology, 2004, 151, 407-412.	1.5	43
188	Serum levels of manganese superoxide dismutase in patients with localized scleroderma. Experimental Dermatology, 2004, 13, 357-360.	2.9	8
189	Tenascin-C upregulation by transforming growth factor-β in human dermal fibroblasts involves Smad3, Sp1, and Ets1. Oncogene, 2004, 23, 1656-1667.	5.9	120
190	Serum matrix metalloproteinase-3 in systemic sclerosis. Archives of Dermatological Research, 2004, 296, 25-9.	1.9	5
191	Elevated circulating soluble CD40 ligand in patients with mixed connective tissue disease. Clinical Rheumatology, 2003, 22, 37-39.	2.2	9
192	Elevated serum levels of manganese superoxide dismutase in patients with eosinophilic fasciitis. Clinical Rheumatology, 2003, 22, 505-505.	2.2	4
193	Plasma plasmin-alpha2-plasmin inhibitor complex levels are increased in systemic sclerosis patients with pulmonary hypertension. British Journal of Rheumatology, 2003, 42, 240-243.	2.3	26
194	Circulating soluble CD40 ligand in patients with eosinophilic fasciitis. Annals of the Rheumatic Diseases, 2003, 62, 190-191.	0.9	11
195	Clinical features of patients with systemic sclerosis accompanied by rheumatoid arthritis. Clinical and Experimental Rheumatology, 2003, 21, 91-4.	0.8	22
196	A case of linear scleroderma with muscle calcification. British Journal of Dermatology, 2002, 146, 1084-1086.	1.5	19
197	Serum levels of tissue inhibitor of metalloproteinases in patients with mixed connective tissue disease. Clinical and Experimental Rheumatology, 2002, 20, 539-42.	0.8	1
198	Differential expression of transforming growth factor-beta receptors in squamous cell carcinoma British Journal of Dermatology, 2001, 145, 840-842.	1.5	3